ICI targeting the PD-1 and CTLA4 immune checkpoints on CD8 T cells or their counter-receptors have become the standard of care for treating immunogenic cancer, such as cutaneous melanoma, but many patients fail to respond [2]. This evidence concerns the gene CD8A and cutaneous melanoma.